World-class founding team includes Prof. Georg Schett, MD, a renowned expert in rheumatology, immunology, and B cell biology, alongside scientific co-founder and board member Frank Nestle, MD, Partner at Deerfield Management and CEO of Deerfield Discovery and Development (3DC)

世界级的创始团队包括风湿病学、免疫学和B细胞生物学领域的著名专家Georg Schett医学博士，以及科学联合创始人兼董事会成员Frank Nestle医学博士，后者是Deerfield Management的合伙人，并担任Deerfield Discovery and Development (3DC)的首席执行官。

Early Phase 1 healthy volunteer data for BLVD101, lead candidate in IgAN, support best-in-class potential and 12-week (quarterly) dosing

BLVD101（IgA肾病领域的领先候选药物）的早期I期健康志愿者数据支持其具备同类最佳潜力及每12周（每季度）给药一次的方案

BLVD101 was invented by Deerfield Management within 3DC, the firm's drug discovery and development engine

BLVD101 由 Deerfield Management 在其药物发现与开发引擎 3DC 内部创立

Boulevard is advancing a broad pipeline of multi-specific antibodies for B cell-driven autoimmune disease

Boulevard 正在推进用于 B 细胞驱动的自身免疫性疾病的多种特异性抗体的广泛研发管线

NEW YORK

纽约

,

，

Aug. 12, 2026

2026年8月12日

/PRNewswire/ -- Boulevard Bio today announced its emergence from stealth with $65 million from founding investor Deerfield Management and early Phase 1 healthy volunteer data for lead candidate BLVD101, a dual BAFF/APRIL-targeting bispecific antibody, supporting a 12-week (quarterly) dosing interval in IgA nephropathy (IgAN).

/美通社/ -- Boulevard Bio 今日宣布结束隐秘运营状态，并获得创始投资者Deerfield Management提供的6,500万美元资金。同时，公司公布了其首要候选药物BLVD101（一种靶向BAFF和APRIL的双特异性抗体）在早期第一阶段健康志愿者试验中的数据，该数据支持在IgA肾病（IgAN）治疗中采用每12周（每季度）一次的给药间隔。

Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), the firm's internal therapeutics research and development engine, Boulevard's approach is grounded in a deep understanding of B cell disease biology, the identification of key mechanisms and targets that drive pathology, and the ability to engineer multi-specific antibodies to address those drivers.

由B细胞生物学领域的先驱创立，并在Deerfield Management旗下的Deerfield Discovery and Development (3DC)（该公司内部的治疗研发引擎）中孵化而成，Boulevard的方法基于对B细胞疾病生物学的深刻理解，对驱动病理的关键机制和靶点的识别，以及设计多特异性抗体以应对这些驱动因素的能力。

The company aims to optimize each of the three candidates in its pipeline to improve the quality of life a chronic illness often erodes..

该公司旨在优化其研发管线中的三种候选药物，以改善慢性疾病常常损害的生活质量。

'Today, over five million patients with B cell-driven autoimmune disease face a lifetime of treatments that may relieve symptoms temporarily but fail to address the underlying cause,' said Mahesh Karande, chief executive officer of Boulevard. 'Leveraging a deep understanding of B cell biology, Boulevard aims to free patients from a lifetime of burdensome treatment, offering durable disease control and, in some cases, the prospect of a cure.

“如今，超过五百万患有B细胞驱动型自身免疫性疾病的患者面临着终身治疗的局面，这些治疗或许能暂时缓解症状，却未能解决根本病因。”Boulevard首席执行官Mahesh Karande表示。“凭借对B细胞生物学的深刻理解，Boulevard旨在使患者摆脱繁重的终身治疗负担，提供持久的疾病控制，并在某些情况下带来治愈的希望。”

Each program in our pipeline was designed and selected for that goal, and the early data from our lead program are a promising indication that the science behind them has the potential to deliver what patients expect and deserve. We are fortunate to work alongside experienced leaders in immunology and rheumatology as we build Boulevard Bio.'.

我们管线中的每个项目都是围绕这一目标设计和筛选的，而我们的首要项目所获得的早期数据令人鼓舞，表明其背后的科学原理有望实现患者所期待和应得的治疗效果。在构建 Boulevard Bio 的过程中，我们有幸与免疫学和风湿病学领域的资深领导者携手合作。

Prof. Georg Schett, MD, co-founder of Boulevard, added, 'Over the past two decades, B cells have become recognized as central drivers of autoimmune disease, but addressing their complex biology likely requires the design of precision medicines that can be combined to target specific, sometimes-overlapping mechanisms and indications.

Boulevard 联合创始人 Georg Schett 医学博士补充道：“在过去二十年中，B 细胞已被公认为自身免疫性疾病的核心驱动因素，但应对其复杂的生物学特性可能需要设计可联合使用的精准药物，以靶向特定的、有时相互重叠的机制和适应症。”

We founded Boulevard to meet that challenge, with multi-target strategies and a thoughtful selection of modalities to appropriately reach key disease drivers and alter the course of chronic illnesses.'.

我们创立Boulevard旨在应对这一挑战，通过多靶点策略和审慎选择的给药方式，精准作用于关键疾病驱动因素，从而改变慢性疾病的进程。

Frank Nestle, MD, Boulevard scientific co-founder, board member, and partner at Deerfield Management, and chief executive officer of 3DC, added, 'Today we are excited to publicly welcome Boulevard Bio into the world – a company incubated at Deerfield with molecules developed inside 3DC, now led by a seasoned team with experience translating complex science into best- and first-in-class medicines.

医学博士弗兰克·内斯特（Frank Nestle）是Boulevard Scientific的联合创始人、Deerfield Management的董事会成员及合伙人，同时担任3DC的首席执行官。他补充道：“今天，我们很高兴向公众欢迎Boulevard Bio正式亮相——这家公司在Deerfield孵化，其分子药物由3DC内部研发，如今由一支经验丰富的团队领导，该团队擅长将复杂的科学成果转化为同类最佳和首创药物。”

Since the company's inception, the Boulevard team has advanced BLVD101 to early clinical data that highlight this compound's potential to achieve durable disease control in a large, underserved patient population. I have great confidence in Boulevard's pipeline and the team driving it forward as they aim to advance differentiated and impactful treatments for patients burdened with lifelong autoimmune diseases.'.

自公司成立以来，Boulevard 团队已推动 BLVD101 进入早期临床研究阶段，所获数据凸显了该化合物在为广大未满足需求患者群体实现持久疾病控制方面的潜力。我对 Boulevard 的管线及其推进团队充满信心，他们致力于为患者提供具有差异化且具影响力的治疗方案，以减轻终身自身免疫性疾病患者的负担。

Boulevard's Pipeline

大道管线

BLVD101

林荫大道101号

BLVD101 (formerly DFX-1092) is a bispecific BAFF/APRIL antibody being developed as a potential treatment for IgAN, with early clinical data to suggest dosing once every twelve weeks. This quarterly dosing profile is designed to align with the rhythm of routine care and the needs of patients living with lifelong autoimmune diseases.

BLVD101（前身为DFX-1092）是一种双特异性BAFF/APRIL抗体，正在开发作为IgAN的潜在治疗药物，早期临床数据表明其给药频率为每十二周一次。这种每季度一次的给药方案旨在与常规护理节奏以及终身患有自身免疫性疾病的患者的需求相契合。

Clinical data from other dual BAFF/APRIL agents suggest that blocking both targets can slow IgAN disease progression, drive reductions in proteinuria and hematuria, and reduce disease burden across renal and systemic autoimmunity, such as lupus and Sjogren's disease. BLVD101 was discovered and developed inside 3DC..

来自其他双靶点BAFF/APRIL药物的临床数据表明，同时阻断这两个靶点可以延缓IgA肾病（IgAN）的疾病进展，降低蛋白尿和血尿水平，并减轻肾脏及全身性自身免疫性疾病（如系统性红斑狼疮和干燥综合征）的疾病负担。BLVD101由3DC公司内部发现并开发。

Interim Phase 1 Data

中期第一阶段数据

In an interim analysis from the ongoing Phase 1 single-ascending dose study in healthy volunteers, BLVD101 was generally well tolerated and maintained a favorable safety profile. Interim pharmacokinetic and pharmacodynamic results show strong IgA suppression and differentiated profile, supporting a 12-week dosing interval..

在正在进行的健康志愿者单次递增剂量I期研究的中期分析中，BLVD101总体耐受性良好，并保持了良好的安全性特征。中期药代动力学和药效学结果显示了强烈的IgA抑制作用和独特的差异化特征，支持每12周给药一次的方案。

BLVD201

林荫大道201号

BLVD201 (formerly MTS-128) is a trispecific CD19/BCMA/CD3 T cell engager designed to deliver a durable immune reset in severe B cell-driven autoimmune disease. Its compact design is built to penetrate deeply into tissue and enable a robust response at a low dose. By engaging both CD19 and BCMA, it aims to clear the antibody-producing compartment along with the cells that replenish it, countering the repopulation that limits single-target approaches.

BLVD201（前身为MTS-128）是一种三特异性CD19/BCMA/CD3 T细胞衔接器，旨在为严重的B细胞驱动型自身免疫性疾病提供持久的免疫重置。其紧凑的设计使其能够深入渗透组织，并在低剂量下引发强效反应。通过同时结合CD19和BCMA，它旨在清除抗体产生区室以及补充该区室的细胞，从而对抗限制单靶点方法的细胞再群体化现象。

This program is in IND-enabling studies and was acquired from METiS TechBio under an exclusive global license in June 2026..

该管线正处于支持新药临床试验申请（IND）的研究阶段，并于2026年6月通过一项全球独家许可协议从METiS TechBio公司引进。

BLVD301

林荫大道301号

BLVD301 is directed at a novel target combination in B cell-driven autoimmune disease, supported by established genetic evidence. The company nominated this development candidate in June 2026.

BLVD301 针对 B 细胞驱动的自身免疫性疾病中的新型靶点组合，并有确凿的遗传学证据支持。该公司于 2026 年 6 月提名该候选药物进入开发阶段。

Leadership & Financing

领导力与融资

Boulevard Bio is led by Mahesh Karande, Chief Executive Officer, and Neil Solomons, MD, Chief Medical Officer. The company's board is chaired by Brian Chow, PhD, Managing Director at Deerfield Management; Deerfield Partner and 3DC CEO Frank Nestle, MD, is scientific co-founder and serves on the board.

Boulevard Bio 由首席执行官 Mahesh Karande 和首席医疗官 Neil Solomons 医学博士领导。公司董事会由 Deerfield Management 的董事总经理 Brian Chow 博士担任主席；Deerfield 合伙人兼 3DC 首席执行官 Frank Nestle 医学博士是科学联合创始人，并在董事会任职。

Boulevard was co-founded by Prof. Georg Schett, MD, a pioneer in immune reset, alongside founding advisor Prof. Jonathan Barratt, PhD, FRCP. Boulevard has raised approximately $65 million in aggregate financing from Deerfield and affiliates in equity capital and convertible notes..

Boulevard 由免疫重置领域的先驱者 Georg Schett 医学博士教授与创始顾问 Jonathan Barratt 哲学博士、英国皇家内科医师学会会员（FRCP）教授共同创立。Boulevard 已从 Deerfield 及其关联公司通过股权资本和可转换票据筹集了总计约 6,500 万美元的融资。

About Boulevard Bio

关于 Boulevard Bio

Boulevard Bio is a precision immunology company built to change the course of B cell-driven autoimmune diseases with targeted, multi-specific medicines designed to set new therapeutic standards. Boulevard is advancing a pipeline of multi-specific antibodies grounded in a deep understanding of B cell disease biology to pair the right targets and modalities to the right disease across the spectrum of B cell-driven autoimmune conditions.

Boulevard Bio 是一家精准免疫学公司，致力于通过靶向、多特异性药物改变 B 细胞驱动的自身免疫性疾病的进程，并树立新的治疗标准。Boulevard 基于对 B 细胞疾病生物学的深刻理解，正在推进一系列多特异性抗体的研发管线，旨在针对各类 B 细胞驱动的自身免疫性疾病，将正确的靶点与治疗模式精准匹配。

The company was founded by pioneers in B cell biology and was incubated by Deerfield Management with molecules developed inside Deerfield Discovery and Development (3DC), the firm's internal therapeutics research and development engine. The company's corporate headquarters are in New York City at Cure, an affiliate of Deerfield..

该公司由B细胞生物学领域的先驱创立，并由Deerfield Management孵化，其分子药物是在Deerfield Discovery and Development（3DC）——即该公司内部的治疗性研发引擎——中开发的。公司总部设在纽约市，位于Deerfield的关联机构Cure。

For more information, visit

欲了解更多信息，请访问

www.boulevardbio.com

www.boulevardbio.com

or follow us on

或在以下平台关注我们

LinkedIn

领英

.

。

Media Contact

媒体联系人

Jason Braco, PhD

杰森·布拉科，博士

Valence Communications

瓦伦斯通信

[email protected]

[email protected]

SOURCE Boulevard Bio

来源：Boulevard Bio

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示